/C O R R E C T I O N -- BioMed Realty/

                    /C O R R E C T I O N -- BioMed Realty/

PR Newswire

SAN DIEGO, April 7, 2014

In the news release, BioMed Realty Invests In Life Science Research Facilities
Leased To Yale University, Yale-New Haven Hospital And Alexion
Pharmaceuticals, issued 07-Apr-2014 by BioMed Realty over PR Newswire, we are
advised by the company that the 4th paragraph, 1st sentence, should read "...a
global pharmaceutical company with a marketed product, Soliris®..." rather
than, "...a global pharmaceutical company with a marketed product,
Solaris®..." as originally issued inadvertently. The complete, corrected
release follows:

  BioMed Realty Invests In Life Science Research Facilities Leased To Yale
  University, Yale-New Haven Hospital And Alexion Pharmaceuticals

    Two properties will aggregate over 1.0 million square feet upon completion

SAN DIEGO, April 7, 2014 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE: BMR)
today announced the investment in two properties, 300 George Street and 100
College Street, in the growing life science research community adjacent to the
Yale School of Medicine in New Haven, Connecticut.

BioMed Realty Trust Logo. (PRNewsFoto/BioMed Realty Trust)

The property at 300 George Street is a nine-story, 519,000 square foot
laboratory and office building, which is anchored by long term leases to Yale
University and the Yale-New Haven Hospital. The second building at 100
College Street, currently under construction, will be a 14-story, fully leased
508,000 square foot laboratory and office project anchored by Alexion
Pharmaceuticals, Inc. Alexion was founded in New Haven in 1992, and will use
the 100 College building as its new global headquarters.

The total project investment, upon completion, is expected to be approximately
$308 million including a continuing partnership interest of Winstanley
Enterprises LLC, which will also continue to provide construction and property
management services for the project.

"This opportunity allows BioMed Realty and Wexford to work with and build upon
the established relationships with world-renowned tenants like Yale
University, Yale-New Haven Hospital and Alexion, a global pharmaceutical
company with a marketed product, Soliris®, and a robust research pipeline,"
said Kent Griffin, President of BioMed Realty. "We look forward to utilizing
our expertise in the well-established life science community in New Haven."

"This is an exciting day for Winstanley Enterprises as we join with BioMed
Realty and Wexford to continue the successful partnerships we have established
with the City of New Haven, Yale University, and the local life sciences
community," observed Carter Winstanley, Principal with Winstanley Enterprises.
"We believe this venture will provide vibrant real estate solutions to
facilitate continued innovation between public and private industry for many
years to come."

"We are excited aboutthis opportunity to expand our university-anchored,
knowledge community platform – particularly with this high quality project
supporting Yale University, Yale-New Haven Hospital and Alexion
Pharmaceuticals," said James Berens, President of Wexford Science &
Technology. "We look forward to working closely with Carter Winstanley and
his talented team supporting the increasingly vibrant New Haven market. Given
the strong foundations which the local community and Yale University have
created in concert with our partner, Winstanley Enterprises, we see New Haven
as a center of excellence which will drive collaboration with top tier
researchers from around the world."

Additional information regarding the investment is available under the
Investor Relations section of BioMed Realty's website at
http://phx.corporate-ir.net/phoenix.zhtml?c=182385&p=irol-IRHome.

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers
optimal real estate solutions for biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty owns or has interests in
properties comprising approximately 17.3 million rentable square feet.
Additional information is available at www.biomedrealty.com. Follow us on
Twitter @biomedrealty.

About Wexford Science & Technology

Wexford Science & Technology, a subsidiary of BioMed Realty, is a real estate
investment and development company specializing in facilities for for-profit
and not-for-profit institutions, especially universities, university-related
research parks and healthcare systems. Wexford brings a unique approach of
collaborating with clients to build knowledge communities which are vibrant,
mixed-use, amenity-rich environments that foster innovation.

About Winstanley Enterprises

Winstanley Enterprises LLC, based in Concord, Massachusetts, invests in and
develops commercial real estate assets. Operating primarily in the Northeast
United States, Winstanley invests across all commercial asset classes with a
particular expertise in the laboratory and life sciences industry. Winstanley
provides a wide range of integrated development, tenant and investor services
through its corporate staff and operating subsidiaries, Winstanley Property
Management LLC and Winstanley Construction Management LLC. Additional
information is available at http://www.winent.com/.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: failure to manage effectively
BioMed Realty Trust, Inc.'s (the "company") growth and expansion into new
markets, or to complete or integrate acquisitions and developments
successfully, including the investments in 300 George Street and 100 College
Street in New Haven, Connecticut; risks and uncertainties affecting property
development and construction, including completion of construction of the 100
College Street property: general risks affecting the real estate industry
(including, without limitation, the inability to enter into or renew leases,
dependence on tenants' financial condition, and competition from other
developers, owners and operators of real estate); adverse economic or real
estate developments in the life science industry or the company's target
markets; risks associated with the availability and terms of financing, the
use of debt to fund acquisitions, developments and other investments, and the
ability to refinance indebtedness as it comes due; failure to maintain the
company's investment grade credit ratings with the ratings agencies; failure
to manage effectively the company's growth and expansion into new markets, or
to complete or integrate acquisitions and developments successfully;
reductions in asset valuations and related impairment charges; risks and
uncertainties affecting property development and construction; risks
associated with tax credits, grants and other subsidies to fund development
activities; risks associated with downturns in foreign, domestic and local
economies, changes in interest rates and foreign currency exchange rates, and
volatility in the securities markets; ownership of properties outside of the
United States that subject the company to different and potentially greater
risks than those associated with the company's domestic operations; risks
associated with the company's investments in loans, including borrower
defaults and potential principal losses; potential liability for uninsured
losses and environmental contamination; risks associated with the company's
potential failure to qualify as a REIT under the Internal Revenue Code of
1986, as amended, and possible adverse changes in tax and environmental laws;
and risks associated with the company's dependence on key personnel whose
continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most recent annual
report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

Logo - http://photos.prnewswire.com/prnh/20091005/BIOMEDLOGO



SOURCE BioMed Realty

Website: http://www.biomedrealty.com/
Contact: Jim Cullinan, (858) 485-9840, james.cullinan@biomedrealty.com
 
Press spacebar to pause and continue. Press esc to stop.